Education
About Us
Working with TipRanks
Follow Us
Guardant Health (GH)
NASDAQ:GH
GH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.81 - $50.89
Previous CloseN/A
Volume639.07K
Average Volume (3M)2.56M
Market Cap
$5.69B
Enterprise Value$3.16B
Total Cash (Recent Filing)$525.54M
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 07, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding123,421,440
10 Day Avg. Volume2,546,748
30 Day Avg. Volume2,564,484
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.70
Price to Cash Flow (P/CF)-22.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.04
Enterprise Value/Ebitda-8.11
Forecast
1Y Price Target
$56.00Price Target Upside19.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Product ExpansionGH has identified demand for Shield in younger patient cohorts, suggesting potential for volume growth outside the Medicare population once commercial reimbursement hits.
Reimbursement ApprovalGH announced that their Shield assay has been approved for ADLT status, and will be reimbursed by FFS Medicare at $1,495.
Revenue GrowthGH is targeting mostly the CMS population and estimates indicate that 2025 Shield revenue of ~$40M+ is achievable, driven by higher average selling prices.
Bears Say
Financial GuidanceGH remains committed to its cash burn target for the Screening business and expects it to reach free cash flow breakeven at $700M in revenue.
Market StrategyThe strategy is likely to focus on only signing private-payer contracts that are at or near the list price, resulting in little degradation from the list price.
---
Ownership Overview
4.01% Insiders
31.59% Mutual Funds
36.59% Other Institutional Investors
10.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GH FAQ
What was Guardant Health’s price range in the past 12 months?
Guardant Health lowest stock price was $15.81 and its highest was $50.89 in the past 12 months.
What is Guardant Health’s market cap?
Guardant Health’s market cap is $5.69B.
When is Guardant Health’s upcoming earnings report date?
Guardant Health’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Guardant Health’s earnings last quarter?
Guardant Health released its earnings results on Feb 20, 2025. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.765 by -$0.135.
Is Guardant Health overvalued?
According to Wall Street analysts Guardant Health’s price is currently Undervalued.
Does Guardant Health pay dividends?
Guardant Health does not currently pay dividends.
What is Guardant Health’s EPS estimate?
Guardant Health’s EPS estimate is -0.75.
How many shares outstanding does Guardant Health have?
Guardant Health has 123,421,440 shares outstanding.
What happened to Guardant Health’s price movement after its last earnings report?
Guardant Health reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.765. Following the earnings report the stock price went down -9.557%.
Which hedge fund is a major shareholder of Guardant Health?
Currently, no hedge funds are holding shares in GH
---
Guardant Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.00 (19.81% Upside)
$56.00 (19.81% Upside)
Blogger Sentiment
Bullish
GH Sentiment 87%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 112.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $164.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.52%
12-Months-Change
Fundamentals
Return on Equity
-4584.47%
Trailing 12-Months
Asset Growth
-16.84%
Trailing 12-Months
Company Description
Guardant Health
Guardant Health, Inc. is a leading precision oncology company that focuses on developing and commercializing blood-based tests for cancer detection, treatment, and monitoring. Operating primarily in the healthcare and biotechnology sectors, the company offers innovative diagnostic solutions that enable personalized cancer care. Its core products include liquid biopsy tests, such as Guardant360, GuardantOMNI, and Guardant Reveal, which provide comprehensive genomic profiling to inform treatment decisions and track disease progression.
---
GH Company Deck
---
GH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, significant product upgrades, and successful cost reductions, indicating a positive trajectory for Guardant Health. However, litigation expenses and challenges with NCCN guidelines presented some obstacles. Overall, the positive developments outweighed the lowlights.Read More>---
GH Revenue Breakdown
91.19% Precision oncology testing
8.81% Development services and other
---
GH Stock 12 Month Forecast
Average Price Target
$56.00
▲(19.81% Upside)
Technical Analysis
Best Analysts Covering GH
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+43.71%
reiterated a buy rating 27 days ago
Copying David Westenberg's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +43.71% per trade.
---